We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00407849
Recruitment Status : Unknown
Verified May 2008 by Federal University of São Paulo.
Recruitment status was:  Active, not recruiting
First Posted : December 5, 2006
Last Update Posted : May 7, 2008
Information provided by:
Federal University of São Paulo

Brief Summary:
Phase I/II study with intravitreal triamcinolone acetonide microspheres(RETAAC)for treatment of diffuse diabetic macular edema unresponsive to laser photocoagulation. Study hypothesis is that single intravitreal injection of RETAAC is safe and efficient compared to conventional treatment. Fifty patients will participate in this study and will be randomized into treatment and observation groups. Efficacy will be evaluated by best corrected visual acuity and macular thickness measured by optic coherence tomography (OCT) after 12 months of treatment.

Condition or disease Intervention/treatment Phase
Diabetic Retinopathy Drug: triamcinolone acetonide Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Intravitreal Triamcinolone Acetonide Microspheres for Treatment of Diffuse Diabetic Macular Edema Unresponsive to Conventional Laser Photocoagulation Treatment.
Study Start Date : October 2006
Actual Primary Completion Date : December 2007
Estimated Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Intervention Details:
  • Drug: triamcinolone acetonide
    Intravitreal injection

Primary Outcome Measures :
  1. Best corrected visual acuity after 12 months of single intravitreal injection of triamcinolone acetonide. [ Time Frame: 12 months ]
  2. Macular thickness measured by optical coherence tomography (OCT) after 12 months of treatment. [ Time Frame: 12 months ]
  3. Safety of intravitreal triamcinolone acetonide after 12 months of treatment. [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetes mellitus (type 1 or 2)
  • Diabetic macular edema in study eye associated to diabetic retinopathy
  • Diffuse macular edema defined as macular thickening determined by biomicroscopy and fluorescein angiography.
  • Best corrected visual acuity between 34 (20/200) and 68 letters (20/50).
  • Macular thickness greater than 300 mcm on OCT.

Exclusion Criteria:

  • Uncontrolled systemic disease
  • Start of medical therapy for diabetes or change in treatment from oral to insulin four months before initial visit.
  • HbA1c levels greater than 10%
  • Presence of retinal venous occlusion, cystoid macular edema,or other condition that would contribute to macular edema.
  • Presence of epiretinal membrane
  • Presence of vitreomacular traction in the study eye.
  • Aphakic or anterior chamber intraocular lens in the study eye.
  • Neovascularization of disc or elsewhere in the study eye.
  • History or presence of choroidal neovascularization in the study eye.
  • Presence of rubeosis irides in the study eye.
  • Eye opacity that interfere with clinical documentation and photography.
  • Intra-ocular surgery 90 days before initial visit.
  • Previous vitrectomy in study eye.
  • Previous history of intravitreal or periocular corticoid or any other intravitreal drug in study eye.
  • Scheduled surgery for study eye.
  • Patients with known allergies to fluorescein, iodo-povidone or any component of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407849

Layout table for location information
Vision Institute, Federal University of Sao Paulo
Sao Paulo, SP, Brazil, 04023-062
Sponsors and Collaborators
Federal University of São Paulo
Layout table for investigator information
Principal Investigator: Jose A Cardillo, M.D Federal University of Sao Paulo
Layout table for additonal information
Responsible Party: Federal University of Sao Paulo, Vision Institute Department of Ophthalmology
ClinicalTrials.gov Identifier: NCT00407849    
Other Study ID Numbers: RETAAC001
First Posted: December 5, 2006    Key Record Dates
Last Update Posted: May 7, 2008
Last Verified: May 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Edema
Diabetic Retinopathy
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action